Halozyme Therapeutics (HALO) FCF Margin (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of FCF Margin data on file, last reported at 46.81% in Q1 2026.

• On a quarterly basis, FCF Margin fell 1106.0% year-over-year to 46.81% in Q1 2026; TTM through Mar 2026 was 44.26%, a 242.0% decrease from a year earlier, with the FY2025 full-year figure at 46.15%, down 100.0% from the prior year.
• FCF Margin for Q1 2026 stood at 46.81%, down from 48.17% in the prior quarter.
• Over the last five years, FCF Margin for HALO reached as high as 64.27% in Q1 2024 and fell as low as 25.43% in Q2 2024.
• Historically, FCF Margin has averaged 44.0% across 5 years, with a median of 44.14% in 2022.
• Across the five-year window, FCF Margin slumped 7183 bps in 2022 and soared 2851 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 44.14% in 2022, then decreased by 14 bps to 38.08% in 2023, then surged by 64 bps to 62.36% in 2024, then dropped by 23 bps to 48.17% in 2025, then decreased by 3 bps to 46.81% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 46.81% in Q1 2026, 48.17% in Q4 2025, and 49.56% in Q3 2025.